← Back to Search

Vasopressin Antagonist

Conivaptan Treatment Group for Cerebral Edema

Phase 1
Waitlist Available
Led By Jesse J Corry, MD
Research Sponsored by Jesse Corry
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 168 hours post-enrollment
Awards & highlights

Summary

The goal of this study is to preliminarily determine/estimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe (i.e., 40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage (ICH) and pressure (ICP). A further goal is to preliminarily estimate whether conivaptan at this same dose can reduce cerebral edema (CE) in these same patients. This study is also an essential first step in understanding the role of conivaptan in CE management. Hypothesis: The frequent and early use of conivaptan at 40mg/day will be safe and well-tolerated, and also reduce cerebral edema, in patients with intracerebral hemorrhage and pressure.

Eligible Conditions
  • Cerebral Edema
  • Stroke

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 168 hours post-enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 168 hours post-enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Patient Tolerance of Conivaptan
Secondary study objectives
Change in Cerebral Edema
Cost
In-hospital Mortality
+1 more

Side effects data

From 2008 Phase 4 trial • 121 Patients • NCT00435591
7%
Constipation
7%
Chest pain
3%
Bile duct obstruction
3%
Bacteraemia
3%
Collapse of lung
3%
Bladder cancer
3%
Renal failure
3%
Pulmonary embolism
3%
Haemodialysis
3%
Cardiac failure congestive
3%
Hyponatraemia
3%
Diarrhoea
3%
Cellulitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Dose Regimen 3
Dose Regimen 1
Dose Regimen 4
Dose Regimen 2

Trial Design

1Treatment groups
Experimental Treatment
Group I: Conivaptan Treatment GroupExperimental Treatment1 Intervention
All seven patients in this arm will receive conivaptan as described in Interventions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Conivaptan
FDA approved

Find a Location

Who is running the clinical trial?

Jesse CorryLead Sponsor
Jesse J Corry, MDPrincipal InvestigatorAllina Health
~1 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top